Infectious Microbes & Diseases, published by Lippincott Williams & Wilkins, is a premier journal dedicated to the exploration and understanding of infectious diseases, microbiology, and epidemiology. With its focused scope and robust peer-review process, the journal aims to disseminate high-quality research that contributes to advancements in the field, making it an essential resource for researchers, healthcare professionals, and students alike. Established in 2019, it has quickly gained recognition, achieving a Q3 rating in categories such as Epidemiology, Infectious Diseases, and Medical Microbiology in 2023, and ranking in the top half of its field within Scopus metrics. Although currently offered as a subscription-based journal, Infectious Microbes & Diseases significantly enriches its disciplines by inviting innovative research and critical review articles, thus playing a vital role in combating the global challenges posed by infectious diseases.

MIKROBIYOLOJI BULTENI, with ISSN 0374-9096, is a prestigious academic journal published by the ANKARA MICROBIOLOGY SOC, located in Ankara, Turkey. Established in 1973, this journal has been a vital conduit for disseminating research in the fields of Immunology, Microbiology, and Infectious Diseases, garnering a reputation as a significant contributor to the scientific community. The journal is currently ranked in the Q3 category within Immunology and Microbiology (miscellaneous), and Infectious Diseases, indicating its impactful presence amidst contemporary research. With access options that may be restricted, MIKROBIYOLOJI BULTENI actively welcomes submissions that advance the understanding of critical microbiological principles and practices, thereby supporting both national and international research efforts. Researchers, professionals, and students are encouraged to explore the latest findings shared in this journal, as it continually shapes the landscape of microbiology and infectious disease studies through its comprehensive and rigorous peer-reviewed publications.

Mediterranean Journal of Infection Microbes and Antimicrobials is a distinguished open-access journal published by GALENOS PUBL HOUSE, dedicated to advancing the understanding of infectious diseases and microbiology. Since its inception in 2011, this journal has been a vital resource for researchers, professionals, and students interested in the intricate world of microbes and their impacts on human health. With its ISSN 2147-673X, the journal has progressively gained visibility, although it currently holds a Q4 ranking in multiple categories including Immunology and Microbiology, and Infectious Diseases for the year 2023. The journal operates from its headquarters in Istanbul, Turkey, and features a rich array of articles that contribute to the field’s body of knowledge. As a platform enhancing the accessibility of research, it invites submissions from global contributors to foster collaboration and innovation in tackling microbial challenges.

The Canadian Journal of Infectious Diseases & Medical Microbiology, published by HINDAWI LTD, is a pioneering open-access journal focused on advancing the fields of infectious diseases and medical microbiology, with its commitment to disseminating innovative research since 2004. With the ISSN 1712-9532 and E-ISSN 1918-1493, the journal is recognized for its high-caliber contributions, achieving a 2023 Q2 ranking in Infectious Diseases and a Q3 ranking in Medical Microbiology, as per the prestigious Scopus rankings. Offering a global platform for researchers and clinicians, the journal is crucial for fostering collaboration and sharing knowledge across borders, emphasizing its role as a significant resource for addressing pressing health challenges. With an HIndex that indicates an increasing influence in the scientific community, the journal maintains its focus on impactful studies that inform clinical practices and policies, while also being available to a diverse audience through its open-access format. Based in Egypt, the journal looks forward to continuing its impact up to 2024 and beyond, serving as a vital forum for scientific exchange and practical applications in the fight against infectious diseases.

BMC Infectious Diseases is a premier open-access journal published by BMC in the United Kingdom, dedicated to the field of infectious diseases. Established in 2001, this journal has been at the forefront of disseminating high-quality, peer-reviewed research, contributing significantly to the global understanding of infectious pathogens and their impact on public health. With a 2023 Scopus ranking of #100 out of 344 in the Medicine - Infectious Diseases category, and a notable Q1 quartile classification, it stands as a vital resource for researchers and professionals alike. Authors benefit from the journal's broad reach and visibility, ensuring their work is accessible to a wide audience. Access options are fully open, allowing for seamless dissemination of knowledge in the ongoing battle against infectious diseases. With an established history of publishing groundbreaking studies, BMC Infectious Diseases plays a crucial role in addressing critical issues and advancing research in the ever-evolving landscape of infectious diseases.

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.

International Journal of Antimicrobial Agents, published by Elsevier, stands as a premier platform in the fields of Infectious Diseases, Microbiology, and Medical Pharmacology. With an impressive impact factor and ranked in the Q1 category across multiple medical disciplines in 2023, this journal is recognized for its contribution to advancing knowledge and understanding in the efficacy and safety of antimicrobial treatments. Its comprehensive scope from 1991 to 2024 allows for the publishing of original research, reviews, and commentary on pressing issues related to antimicrobial resistance, treatment strategies, and pharmacological innovations. With a strong emphasis on high-quality research as reflected in its Scopus rankings, the journal is an essential resource for researchers, clinicians, and students dedicated to improving patient outcomes in the face of evolving microbiological challenges. Engage with the latest findings and methodologies through this vital academic resource, available in print and online, from the heart of the Netherlands.

Current Treatment Options in Infectious Diseases, published by SpringerNature, is a pivotal peer-reviewed journal dedicated to advancing the field of infectious disease management and therapy. With a focus on the latest treatment modalities, this journal serves as a vital resource for researchers, healthcare professionals, and students striving to improve patient outcomes in infectious diseases. Although it is not an open-access journal, it offers valuable insights through carefully curated articles that emphasize evidence-based practices and innovative approaches in the treatment landscape. By fostering a cross-disciplinary dialogue, Current Treatment Options in Infectious Diseases aims to bridge the gap between research and clinical application, making it an essential platform for staying abreast of developments in this rapidly evolving field.

Infectious Diseases and Clinical Microbiology is a pivotal journal dedicated to advancing our understanding of infectious diseases through rigorous scientific research and clinical practices. Published by DOC DESIGN INFORMATICS CO LTD, this journal serves as a vital platform for researchers, healthcare professionals, and students keen on enhancing their knowledge of microbiological sciences and the clinical implications of infectious agents. With an ISSN of 2667-646X, it aims to disseminate significant findings in the field, enriching the scholarly dialogue surrounding infectious diseases. While currently operating under a traditional access model, the journal encourages global collaboration and knowledge sharing, striving to make a meaningful impact in tackling the challenges posed by infectious diseases. Its content aims to bridge the gap between laboratory research and clinical application, making it an essential resource in the contemporary landscape of global health.

Infection and Drug Resistance, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the critical fields of infectious diseases and pharmacology. Since its establishment in 2008, this journal has emerged as a vital resource for researchers, professionals, and students alike, offering thorough insights into the mechanisms of drug resistance and the effectiveness of various therapeutic interventions. With an impressive 2023 impact factor placing it in the Q2 category across multiple relevant disciplines, including Infectious Diseases and Pharmacology, it serves as a significant platform for high-quality research dissemination. Infection and Drug Resistance aims to foster a deeper understanding of the evolving challenges in managing infectious diseases and enhancing drug efficacy, contributing to the global discourse on public health. The journal's commitment to open access ensures that vital knowledge is readily available to promote broader scholarly engagement and innovation.